Drug Profile
Research programme: monoclonal antibody therapeutics - Curacyte
Alternative Names: VTR 4Latest Information Update: 26 Apr 2007
Price :
$50
*
At a glance
- Originator Scottish National Blood Transfusion Service
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Systemic inflammatory response syndrome
Most Recent Events
- 10 Jun 2002 VitaResc Biotech has been acquired by, and merged into, Curacyte AG
- 03 Nov 1999 Preclinical development for Systemic inflammatory response syndrome in Germany (Unknown route)